Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

The Pharma Data

OCTOBER 21, 2020

Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc.

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

Drug Discovery World

MAY 11, 2023

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response.

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

JULY 21, 2021

Pfizer and Biovac have worked together since 2015 on the sterile formulation, fill, finish and distribution of the Prevenar 13 vaccine. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

OCTOBER 4, 2023

More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. This approach – immune-stimulating antibody conjugates (ISACs) – uses a payload that stimulates the innate and adaptive immune responses, recruiting tumour-fighting T cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Discovery World

JULY 31, 2023

Since 2010, investments in the field have grown and the number of therapies launched globally has tripled. The expansion of nucleic acid-based therapies One factor contributing to increased investment during this time was the success of the mRNA-based Covid-19 vaccine.

DNA 130

DNA Vaccine Therapies Production 130

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. Existing therapies have been focused on eliminating the cancer cells and/or on preventing its progression by using a combination of chemotherapy, radiotherapy, and surgical approaches.

Research 130

Research Therapies Immune Response Clinical Trials 130

The Pharma Data

SEPTEMBER 8, 2021

Updated Phase 3 CheckMate -577 disease-free survival (DFS) results for adjuvant Opdivo treatment vs. placebo for patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy (CRT). Summary of Presentations. All times noted are Central European Summer Time (CEST). Abstract Title.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses. during 2015-2016. IMPORTANT SAFETY INFORMATION.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

MARCH 29, 2022

To date, Opdivo-based therapies have shown improved efficacy in the neoadjuvant or adjuvant treatment of four tumor types: NSCLC, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

The Pharma Data

JULY 8, 2021

Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018. Food and Drug Administration Breakthrough Therapy Designation was granted to tezepelumab in September 2018 for patients with severe asthma, without an eosinophilic phenotype.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

APRIL 16, 2021

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib. professor of medicine and urology department head, Jena University Hospital. About Opdivo.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

The Pharma Data

APRIL 11, 2021

Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophageal/gastroesophageal junction cancer, bladder cancer and melanoma. 10.26), meaning 10% or less of their tumor cells remained after neoadjuvant therapy. About Opdivo.

Trials 52

Trials Treatment Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Adults with COVID-19 ARDS As cases of COVID-19 surge in the United States and globally, deaths continue to increase from ARDS in ventilator-dependent patients as a result of an overactive immune response in the lungs to COVID-19. CDC Facts and Figures 2015. Decision Resources: Chronic Pain December 2015 8.TEMCELL

Treatment 40

Treatment Trials Production Disease 40

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. It’s a commitment that extends beyond introducing novel therapies.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

JUNE 30, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Trials FDA Approval Disease 52

Drug Discovery World

SEPTEMBER 29, 2022

In 2015, after a 15-year effort to vaccinate against rubella virus (which is usually administered at the same time with vaccines against measles and mumps), the Americas were declared free of endemic transmission of rubella 13. . The immune response to human CMV. The potential future of mRNA in CMV prevention . Cheeran, M.

Vaccine 130

Vaccine Immune Response Virus Disease 130

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

SugarCone Biotech

MAY 28, 2019

These talks, by Ron Germain and Michael Dustin, presented the lives of immune cells in a series of diverse locations with a complex cast of characters. These investigators work to understand the cell biology that supports a productive immune encounter, and this depends in part on location as much as it does on cell type.

Immune Response 52

Immune Response Therapies Engineering Regulations 52